多巴丝肼联合普拉克索治疗帕金森病30例疗效观察

Curative effects of levodopa and benserazide hydrochloride combined with pramipexole on Parkinson's disease in 30 patients

目的:观察多巴丝肼联合普拉克索治疗帕金森病的疗效及其对神经递质、氧化应激反应的影响。方法:选取金华市人民医院2020年1月至2022年2月收治的帕金森病患者90例为观察对象,采用随机数字表法分为多巴丝肼组、普拉克索组、联合治疗组各30例。多巴丝肼组予多巴丝肼治疗,普拉克索组予普拉克索治疗,联合治疗组予多巴丝肼联合普拉克索治疗,均治疗12周。比较三组临床疗效及脑神经递质[多巴胺(DA)、5-羟色胺(5-HT)、去甲肾上腺素(NE)与P物质(SP)水平]、氧化应激反应[超氧化物歧化酶(SOD)、丙二醛(MDA)、同型半胱氨酸(Hcy)]的变化。结果:联合治疗组总有效率为96.67%(29/30),高于多巴丝肼组的66.67%(20/30)、普拉克索组的76.67%(23/30),差异有统计学意义(χ^(2)=8.65,P<0.05)。治疗后,联合治疗组DA、5-HT、NE、SP、SOD、MDA、Hcy分别为(9.05±1.24)ng/mg、(89.49±10.69)μg/L、(15.16±1.36)ng/mg、(102.8±15.36)μg/L、(88.40±10.04)kU/L、(5.5±2.31)μmol/L、(9.20±3.36)μmol/L,均优于多巴丝肼组的(6.61±1.02)ng/mg、(68.52±9.52)μg/L、(12.33±1.24)ng/mg、(151.64±16.03)μg/L、(74.99±7.28)kU/L、(9.27±3.07)μmol/L、(13.52±3.64)μmol/L及普拉克索组的(7.22±1.09)ng/mg、(79.52±10.20)μg/L、(13.92±1.31)ng/mg、(131.30±15.65)μg/L、(80.59±8.24)kU/L、(7.53±2.93)μmol/L、(11.35±3.71)μmol/L(F=38.53、32.05、35.49、-73.42、18.42、-22.65、-12.13,均P<0.05)。结论:多巴丝肼联合普拉克索用于帕金森病疗效显著,可有效改善脑神经递质,调节氧化应激反应。

Objective:To investigate the efficacy of levodopa and benserazide hydrochloride combined with pramipexole in the treatment of Parkinson's disease in 30 patients and their effects on neurotransmitters and oxidative stress response.Methods:A total of 90 patients with Parkinson's disease admitted to Jinhua People's Hospital from January 2020 to February 2022 were included in this study.They were randomly assigned to undergo treatment with levodopa and benserazide hydrochloride(levodopa and benserazide hydrochloride group),pramipexole(pramipexole group),or their combination(combined therapy group),with 30 patients in each group.All patients were treated for 12 consecutive weeks.Clinical efficacy,levels of brain neurotransmitters(dopamine,5-hydroxytryptamine,norepinephrine,and substance P),and oxidative stress response(superoxide dismutase,malondialdehyde,homocysteine levels)were compared among the three groups.Results:Total response rate in the combined therapy group was 96.67%(29/30),which was significantly higher than 66.67%(20/30)in the levodopa and benserazide hydrochloride group and 76.67%(23/30)in the pramipexole group(χ^(2)=8.65,P<0.05).After treatment,dopamine,5-hydroxytryptamine,norepinephrine,substance P,superoxide dismutase,malondialdehyde,and homocysteine levels in the combined therapy group were(9.05±1.24)ng/mg,(89.49±10.69)μg/L,(15.16±1.36)ng/mg,(102.8±15.36)μg/L,(88.40±10.04)kU/L,(5.5±2.31)μmol/L,and(9.20±3.36)μmol/L,respectively,which were superior to(6.61±1.02)ng/mg,(68.52±9.52)μg/L,(12.33±1.24)ng/mg,(151.64±16.03)μg/L,(74.99±7.28)kU/L,(9.27±3.07)μmol/L,and(13.52±3.64)μmol/L in the levodopa and benserazide hydrochloride group and(7.22±1.09)ng/mg,(79.52±10.20)μg/L,(13.92±1.31)ng/mg,(131.30±15.65)μg/L,(80.59±8.24)kU/L,(7.53±2.93)μmol/L,(11.35±3.71)μmol/L in the pramipexole group(F=38.53,32.05,35.49,-73.42,18.42,-22.65,-12.13,all P<0.05).Conclusion:Levodopa and benserazide hydrochloride combined with pramipexole are highly effective on Parkinson's disease.The combined therapy can effectively improve brain neurotransmitters and regulate oxidative stress response.